Sophia Genetics SA key statistics and ratios

In fiscal 2025, Sophia Genetics SA had return on equity of -110.0%, an operating margin of -91.8%, debt equal to 101.2% of equity and a current ratio of 1.96. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sophia Genetics SA: financial ratios, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	70.3%	62.3%	62.4%	65.7%	68.8%	67.4%	67.4%
Operating margin	—	−131.6%	−176.7%	−184.7%	−120.0%	−102.1%	−91.8%
Net margin	−133.2%	−138.5%	−182.1%	−183.9%	−126.6%	−95.9%	−102.2%
Free-cash-flow margin	−130.3%	−113.3%	−149.9%	−156.0%	−87.7%	−68.7%	−47.2%
Return on equity	−151.8%	−64.1%	−39.2%	−36.8%	−44.9%	−50.4%	−110.0%
Return on assets	—	−29.8%	−32.6%	−31.0%	−35.1%	−34.6%	−49.6%
Asset turnover	—	0.21	0.18	0.17	0.28	0.36	0.49
Current ratio	—	5.08	9.89	7.32	4.16	3.71	1.96
Debt to equity	17.2%	3.3%	0.0%	0.0%	0.0%	13.7%	101.2%
Interest cover (operating income ÷ interest)	—	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	59.2%	65.5%	65.7%	74.4%	59.3%	52.7%	44.3%
Capital spending as % of revenue	5.3%	1.6%	6.6%	8.6%	2.4%	0.4%	0.7%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 7 checks passed · December 31, 2025

What it owns · $163m

Short-term assets $99mLonger-term assets $64m

What it owes, and who funded it · $163m

Short-term liabilities $51mLonger-term liabilities $65mShareholders' equity $47m

Short-term assets cover short-term liabilities $99m of assets due within a year against $51m of liabilities due within a year.
Short-term assets cover long-term liabilities $99m short-term assets against $65m of longer-dated liabilities.
More cash than debt $70m of cash against $48m of debt.
Debt below 40% of shareholders' equity Debt is 101% of equity.
Debt burden no higher than five years ago Debt to equity moved from 0% to 101% over five years.
A year's operating cash flow covers at least 20% of debt −$36m of operating cash flow against $48m of debt.
Operating profit covers interest at least five times over Operating income of −$71m against $5m of interest.

From Sophia Genetics SA's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: OPRX vs SOPH CCLD vs SOPH AMWL vs SOPH HCTI vs SOPH

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Sophia Genetics SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sophia Genetics SA.